1. In Vivo
  2. >>Business Strategy

Ensuring The Next Generation Of Health Care Professionals: Still An Unmet Need

Health Care Is At A ‘Crucial Point’ On Its Journey To The Future Says Philips

 
• By Ashley Yeo

For its fifth annual Future Health Index, Royal Philips chose to focus on the insights and needs of health care professionals below the age of 40, a group that often feels unheard, and yet will form the basis of the workforce over the next two decades. Getting it right from their point of view is vital.

Business_People_Shadows

“The findings of the Future Health Index (FHI) 2020 demonstrate that we are at a crucial moment in the journey to the future of health care.” So said Jan Kimpen, chief medical officer at Royal Philips NV, as the group published the fifth annual edition in its series of FHI reports. The survey, of some 3,000 young doctors and nurses from 15 countries, reveals that unmet needs can apply to health care providers and health care professionals (HCPs), as well as patients.

The goal of the Philips Future Health indexes is to understand customers better and cater to their needs, especially in relation to technology, Kimpen said in comments to In Vivo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.